Advanced Esophageal Squamous Cell Carcinoma Clinical Trials

6 recruiting

Advanced Esophageal Squamous Cell Carcinoma Trials at a Glance

11 actively recruiting trials for advanced esophageal squamous cell carcinoma are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Guangzhou, Beijing, and Brisbane. Lead sponsors running advanced esophageal squamous cell carcinoma studies include Nanfang Hospital, Southern Medical University, Mayo Clinic, and Hummingbird Bioscience.

Browse advanced esophageal squamous cell carcinoma trials by phase

Treatments under study

About Advanced Esophageal Squamous Cell Carcinoma Clinical Trials

Looking for clinical trials for Advanced Esophageal Squamous Cell Carcinoma? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced Esophageal Squamous Cell Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced Esophageal Squamous Cell Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2

A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

Advanced Esophageal Squamous Cell Carcinoma
Shanghai Junshi Bioscience Co., Ltd.280 enrolled1 locationNCT07484724
Recruiting

Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC

Locally Advanced Esophageal Squamous Cell Carcinoma
Shandong Provincial Hospital30 enrolled1 locationNCT07549100
Recruiting
Phase 1Phase 2

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

Squamous Cell CarcinomaAdvanced or Metastatic Squamous Non-Small Cell Lung CancerAdvanced Head and Neck Squamous Cell Carcinoma+4 more
Hummingbird Bioscience398 enrolled20 locationsNCT05910827
Recruiting
Phase 2

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Urothelial CarcinomaEsophageal CarcinomaHepatocellular Carcinoma+28 more
Mayo Clinic50 enrolled1 locationNCT06265285
Recruiting
Phase 2

A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Neoadjuvant TherapyLocally Advanced Esophageal Squamous Cell Carcinoma
Sun Jing30 enrolled1 locationNCT06356688
Recruiting
Phase 2

A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma

Locally Advanced Esophageal Squamous Cell Carcinoma
Nanfang Hospital, Southern Medical University34 enrolled1 locationNCT06843889
Recruiting
Phase 2Phase 3

Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma

Locally Advanced Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital120 enrolled1 locationNCT06907602
Recruiting
Phase 2

AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients

ESCCAdvanced Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital30 enrolled1 locationNCT06489197
Recruiting
Phase 2

Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma

Advanced Esophageal Squamous Cell Carcinoma
Nanfang Hospital, Southern Medical University100 enrolled1 locationNCT05214222
Recruiting
Phase 2

A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma

Advanced Esophageal Squamous Cell Carcinoma
Shanghai Runshi Pharmaceutical Technology Co., Ltd138 enrolled1 locationNCT06512428
Recruiting
Phase 2

Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)

Locally Advanced Esophageal Squamous Cell Carcinoma
Sun Yat-sen University140 enrolled1 locationNCT06187597